The small-molecule Bcl-2 inhibitor HA14-1 sensitizes cervical cancer cells, but not normal fibroblasts, to heavy-ion radiation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18774194.
- Also identified by DOI 10.1016/j.radonc.2008.08.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This is the first study to demonstrate that the small-molecule Bcl-2 inhibitor HA14-1 renders human cervical cancer cells and their Bcl-2 overexpressing radioresistant counterparts, but not normal fibroblasts, more susceptible to heavy ions. Thus, Bcl-2 may be an attractive target for improving the efficacy of heavy-ion therapy.
Medical subject headings
- Benzopyrans
- Heavy Ions
- Nitriles
- Photosensitizing Agents
- Proto-Oncogene Proteins c-bcl-2
- Uterine Cervical Neoplasms